- Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Urinary Tract Infections
Interventions: Drug: Trimethoprim sulfamethoxazole, amoxicillin-clavulanate, cefixime, or cephalexin; Drug: Placebo
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Children's Hospital of Pittsburgh; University of Pennsylvania; Westat; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Cystic Fibrosis
Interventions: Drug: Inhaled Vancomycin; Drug: Placebo (Sterile Water); Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX); Drug: Doxycycline; Drug: Mupirocin Nasal Ointment; Drug: 4% chlorhexidine gluconate liquid skin cleanser
Sponsors: Johns Hopkins University; Michael Boyle; Case Western Reserve University; Cystic Fibrosis Foundation
Not yet recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: Doxycycline; Drug: Ipilimumab; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either 500 mg of Ciprofloxacin (oral); Drug: or 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii Cancer Research Center; University of Vermont
Not yet recruiting - verified April 2012 - Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine; Procedure: Phlebotomy
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified April 2012 - Condition: Chronic Periodontitis
Interventions: Drug: Amoxicillin-Metronidazole combination plus oral rinse; Device: scaling and root planing
Sponsors: Georgia Health Sciences University; Georgia Health Sciences University; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy; Drug: TNF inhibitors
Sponsors: Columbia University; Columbia University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Hydroxychloroquine; Drug: IL-2
Sponsors: University of Pittsburgh; University of Pittsburgh; Prometheus Laboratories
Recruiting - verified March 2012 - Condition: Dehisced Surgical Wounds
Interventions: Drug: NanoDOX 1% doxycycline monohydrate Hydrogel; Drug: placebo hydrogel
Sponsors: Nanotherapeutics, Inc.; Nanotherapeutics, Inc.; Department of Defense
Not yet recruiting - verified April 2012 - Conditions: Kidney Failure, Chronic; Cardiovascular Disease; Arteriosclerosis
Interventions: Drug: Hydroxychloroquine; Other: Placebo comparator
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Condition: Drug Induced Constipation
Interventions: Drug: Nektar 118; Drug: Quinidine; Drug: Quinidine placebo; Drug: Morphine
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: CAZ-AVI; Drug: metronidazole; Drug: CAZ-AVI + metronidazole
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified March 2012 - Condition: Rosacea
Interventions: Drug: Metronidazole Topical Gel 1%; Drug: Metronidazole Topical Gel 1% (Metrogel); Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified January 2012 - Conditions: Histological Evidence of Metastatic Clear Cell Renal Cell Carcinoma; That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens; With Evidence of Progressive Disease on or Within 6 Months; of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous; Therapy With Bevacizumab, IL2, or Interferon Are Permitted.
Interventions: Drug: Hydroxychloroquine; Drug: RAD001
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Conditions: Advanced Adenocarcinoma; Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ); Drug: Gemcitabine
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Conditions: Skin and Soft Tissue Abscess; Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Intervention: Drug: Oral Clindamycin
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital
Recruiting - verified December 2011 - Conditions: Kidney Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Drug: hydroxychloroquine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: HIV; PCP; Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily; Drug: Atovaquone 1500 mg twice daily
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified October 2011 - Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: C. Difficile Infection
Intervention: Drug: metronidazole
Sponsors: State University of New York at Buffalo; State University of New York at Buffalo
Not yet recruiting - verified November 2011 - Condition: Breakthrough Bleeding
Intervention: Drug: Doxycycline
Sponsors: University of Hawaii; University of Hawaii; Charles Drew University of Medicine and Science; Meharry Medical College
Recruiting - verified March 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LY2216684; Drug: Quinidine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011 - Condition: Complicated Intra-abdominal Infection
Interventions: Drug: CXA-201 and metronidazole; Drug: Meropenem
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified March 2012 - Condition: Complicated Intra-abdominal Infection
Interventions: Drug: CXA-201 and metronidazole; Drug: Meropenem
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Brain Cancer
Interventions: Drug: Temozolomide; Drug: Memantine; Drug: Mefloquine; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Congenital Nasolacrimal Duct Obstruction
Interventions: Drug: Besifloxacin; Drug: polymyxin b/trimethoprim - ophthalmic
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Bausch & Lomb, Inc.
Recruiting - verified September 2011 - Condition: Rosacea
Interventions: Drug: oral doxycycline and topical metronidazole; Drug: oral doxycycline; Drug: placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Conditions: Lung Transplant Infection; Receiving Posaconazole
Intervention: Other: collection of blood samples for PK testing
Sponsors: University of Pittsburgh; University of Pittsburgh; Merck
Not yet recruiting - verified August 2011 - Conditions: Bone Metastases; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: hydroxychloroquine; Radiation: radiation therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine; Drug: Hydroxychloroquine; Radiation: Proton Radiation Therapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified December 2011 - Condition: Myeloma
Interventions: Drug: Hydroxychloroquine; Drug: Rapamycin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Congenital Heart Block; Neonatal Lupus; Autoantibody-Associated Heart Block
Intervention: Drug: Hydroxychloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified June 2011 - Condition: Trichomonas Vaginitis
Interventions: Drug: oral metronidazole; Drug: neo penotran forte; Drug: neo penotran forte once a day
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Embil Pharmaceutical Co. Ltd
Recruiting - verified January 2012 - Conditions: Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
Interventions: Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole; Drug: Minocycline; Drug: Mupirocin; Drug: chlorhexidine gluconate oral rinse; Drug: 2% Chlorhexidine solution wipes; Behavioral: Environmental Decontamination
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; University of Washington; University of Colorado, Denver; Texas Children's Hospital; University of Alabama at Birmingham; St. Louis Children's Hospital; Cook Children's Medical Center; University of Michigan Health System
Recruiting - verified January 2012 - Condition: Rectal Cancer
Interventions: Drug: Rifaximin; Drug: Placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate CancerCondition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012 - Condition: Rosacea
Interventions: Drug: Doxycycline; Other: Placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified February 2012 - Condition: Alcohol or Other Drugs Effects
Interventions: Drug: Alcohol + Caffeine Beverage; Drug: Alcohol + Caffeine-placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Hydroxychloroquine; Drug: Hydroxychloroquine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital
Recruiting - verified March 2012 - Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Bacterial Vaginosis; Trichomoniasis; Candidiasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Malaria
Intervention: Other: Artemether-lumefantrine
Sponsors: Novartis; Novartis Pharmaceuticals; Centers for Disease Control and Prevention
Recruiting - verified April 2012 - Condition: Urinary Tract Infection
Interventions: Other: Sweetened, dried cranberries; Other: Strawberry Fruit Pieces; Other: Sweetened, dried cranberries; Other: Sweetened, dried cranberries; Other: Strawberry Fruit Pieces; Other: No treatment
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Ocean Spray Cranberries, Inc.
Recruiting - verified November 2011 - Conditions: Rectal Cancer; Colon Cancer; Metastasis; Adenocarcinoma
Interventions: Drug: Hydroxychloroquine; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil; Drug: 5-fluorouracil; Drug: Bevacizumab
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Interventions: Drug: micafungin; Drug: posaconazole
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Astellas Pharma US, Inc.
Recruiting - verified January 2012 - Conditions: Obesity; Pharmacokinetics; MRSA; Tuberculosis; PCP
Intervention: Drug: Sulfamethoxazole/trimethoprim
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; National Center for Research Resources (NCRR); University of Texas Southwestern Medical Center
Recruiting - verified February 2012 - Conditions: Obesity; Leprosy; Tuberculosis
Intervention: Drug: Dapsone
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Condition: Pelvic Inflammatory Disease
Interventions: Drug: ceftriaxone, doxycycline, and placebo; Drug: ceftriaxone, doxycycline, metronidazole
Sponsors: University of Pittsburgh; Harold Wiesenfeld; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Seroma
Interventions: Drug: doxycycline; Other: No intervention
Sponsors: North Shore Long Island Jewish Health System; Staten Island University Hospital
Recruiting - verified January 2010 - Condition: Prostate Cancer
Interventions: Biological: fowlpox-PSA-TRICOM vaccine; Biological: vaccinia-PSA-TRICOM vaccine; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Genotype; Retinal Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: Hydroxychloroquine (HC)
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Leishmaniasis, Cutaneous
Intervention: Drug: WR 279,396
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed National Military Medical Center; Walter Reed Army Institute of Research (WRAIR)
Recruiting - verified February 2012 - Conditions: Rheumatoid Arthritis; Insulin Resistance
Intervention: Drug: Hydroxychloroquine
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Hydroxychloroquine; Drug: Gemcitabine
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Catheter-Associated Urinary Tract Infection
Interventions: Drug: Bactrim; Other: Placebo
Sponsors: The Cleveland Clinic; The Cleveland Clinic; American Urogynecologic Society
Recruiting - verified February 2012 - Condition: Cystic Fibrosis
Interventions: Drug: Doxycycline; Other: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Cystic Fibrosis Foundation
Recruiting - verified May 2012 - Condition: Fungal Infection
Interventions: Drug: posaconazole; Drug: Dextrose 5% in water (1) posaconazole (2); Drug: posaconazole; Drug: posaconazole; Drug: posaconazole; Drug: Posaconazole
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
Intervention: Drug: pyrimethamine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Lymphoma Research Foundation
Recruiting - verified February 2012 - Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Suramin + Docetaxel + Carboplatin; Drug: Placebo + Docetaxel + Carboplatin
Sponsors: Optimum Therapeutics, LLC; Optimum Therapeutics, LLC
Recruiting - verified June 2011 - Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: Pyrimethamine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Muscular Dystrophy Association
Recruiting - verified July 2011 - Conditions: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week); Drug: Chloroquine Low Dose (250mg/week); Procedure: Breast Biopsy
Sponsors: Inova Health Care Services; Inova Health Care Services; George Mason University; Department of Defense; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: sodium stibogluconate
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011 - Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: XELOX regimen; Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Familial Adenomatous Polyposis
Interventions: Drug: eflornithine (DFMO); Drug: acetylsalicylic acid (aspirin); Other: placebo; Other: laboratory biomarker analysis; Other: gene expression analysis; Other: telephone-based intervention; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: protein expression analysis
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012 - Condition: C. Trachomatis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Hydroxychloroquine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Stanford University; Yale University; University of Maryland; Genentech
Recruiting - verified April 2012 - Condition: Melanoma (Skin)
Intervention: Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Cryptococcal Meningitis; HIV Infections
Interventions: Drug: Fluconazole; Drug: Amphotericin B
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Pulp Necrosis
Interventions: Drug: Double Antibiotic Paste; Drug: Triple Antibiotic Paste; Drug: Mineral Trioxide Aggregate
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified March 2012 - Condition: Abscess
Interventions: Drug: Trimethoprim-sulfamethoxazole; Drug: Sugar pill
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; Blue Cross Blue Shield
Recruiting - verified June 2011 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Cancer
Interventions: Drug: hydroxychloroquine; Drug: sunitinib malate
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Cephalexin; Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Clindamycin; Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Prostate Cancer
Intervention: Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Bacterial Vaginosis
Interventions: Other: No Intervention; Drug: Metronidazole
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Leishmaniasis
Intervention: Drug: Sodium Stibogluconate (SSG)
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed Army Medical Center
Recruiting - verified May 2012 - Conditions: Neuroblastoma; Medulloblastoma
Interventions: Drug: Nifurtimox; Drug: Cyclophosphamide; Drug: Topotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Bayer
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Intervention: Other: F-MISO PET scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Intervention: Radiation: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012 - Conditions: Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified July 2007 - Condition: Prostate Cancer
Interventions: Radiation: Samarium Sm 153 lexidronam pentasodium; Biological: Sargramostim; Biological: Recombinant vaccinia-TRICOM vaccine; Biological: Recombinant fowlpox-TRICOM vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Vesico-Ureteral Reflux; Urinary Tract Infections
Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Condition: Cysticercosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
 |
Antiprotozoal Agents Clinical Trials |
